Israel's Ehud Barak, Out of Politics, Turns to Medical Marijuana
(Bloomberg) -- Israel's most decorated soldier is going to pot.
Ehud Barak, a former prime minister and military commander-in-chief, rang the bell Wednesday to open trading on the Tel Aviv Stock Exchange for InterCure Ltd., a biomedical company he chairs. The company recently completed its acquisition of Canndoc Pharma, which holds one of just eight coveted licenses from Israel's Health Ministry to grow medical-grade marijuana, making it the only publicly traded pot producer in the Holy Land.
Barak, whose other business ventures range from cyber security to emergency-rescue technology, hasn't exactly become a stoner since leaving public service in 2013. InterCure executives approached him several months ago with a business proposal, he said, and after doing due diligence, he signed up.
“I have no familiarity with cannabis: I never took a puff in my life, never took a bite of anything, never put any drops under my tongue,” Barak told a crowd Wednesday at the exchange. “But I studied the issue, read material and understood that cannabis for medical use is something real, with real potential impact.”
InterCure shares were up 30 percent to 4.22 shekels as of 2:02 p.m. Wednesday in Tel Aviv, their largest gain since June. The company announced on Wednesday it had raised $12 million in a private placement to investors.
While Canndoc already supplies medical marijuana to patients with doctors' prescriptions -- which can be filled at Israel's largest pharmacy chain -- the eventual prize is international export. Many in the local industry expected the Netanyahu government to approve export of medical-grade weed last April, but the issue ultimately was deferred for further study.
Israelis are big-time pot smokers -- the country has the highest rate of recreational use in the world, according to one 2017 poll -- and penalties for personal use have been relaxed in recent years. It's not unusual to stroll through a pungent cloud on the streets of Tel Aviv, where people roll joints at sidewalk cafes and every few blocks there's a head shop selling bongs, vaporizers and other paraphernalia. Green Leaf, a party that seeks full marijuana legalization, fields a Knesset slate in every election, though it has yet to win a seat in parliament.
But it's in medical marijuana where Israel really hopes to emerge as a leader. Hebrew University chemist Raphael Mechoulam is credited with isolating THC -- the psychoactive ingredient in marijuana -- in his lab in the 1960s, and the country is considered among the international pathbreakers in medical marijuana research. Skeptics say some of the medical benefits marijuana advocates claim have yet to be proven scientifically.
Barak, in his presentation Wednesday, struggled to sound out the long scientific name for THC, as well as for CBD, a spectrum of compounds in the plant that are being tapped for their medicinal applications. Clearly, Barak said, he still needs to learn more about the subject.
“I hope we're going to build a global company, based in Israel,” he said. "One that will bring relief to a lot of people.”
To contact the reporter on this story: Michael S. Arnold in Tel Aviv at marnold48@bloomberg.net
To contact the editors responsible for this story: Riad Hamade at rhamade@bloomberg.net, Amy Teibel
©2018 Bloomberg L.P.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.